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A
utoimmune diabetes in the popular nonobese
diabetic (NOD) mouse results from a T-cell–
mediated destruction of the insulin-producing
-cells (1) and serves as a model for human
type 1 diabetes (2,3). The mechanisms that initiate early
peri-islet inﬂammation and the destructive components
that arise later speciﬁcally targeting -cells occur naturally
in NOD mice (2,3). Two obstacles hinder our progress in
unraveling the rudiments of type 1 diabetes: 1) the identi-
ﬁcation of the antigens involved in the earliest stages of
autoimmunity and 2) the event(s) that provokes the initial
autoimmunity and loss of homeostasis in the islets. The
hope has been that the former would aid in sorting out the
latter.
The NOD mouse provides us with a framework for
understanding T-cell–mediated autoimmune diseases in
general. Discovering the nature of the initial organ-
inﬁltrating cells is a key to the prevention of inﬂammatory
autoimmune disease. Does spontaneous insulitis, which
precedes type 1 diabetes, begin by a random accumulation
of lymphocytes into the pancreatic islets, or is there an
essential temporal pattern to the activation and recruit-
ment of organ-speciﬁc lymphocytes? An answer to this
question seems essential to our grasping the complexities
of disease susceptibility and onset. Infectious agents have
long been postulated to have a role as incendiary triggers
for abnormal tissue inﬂammation and the genesis of a
tissue-speciﬁc adaptive autoimmune/immune response.
Either through molecular mimicry (4,5) or cytopathic
means (6), an invading microorganism could create an
environment of sufﬁcient driving force to overcome innate
tolerance to self-molecules and tissues. Although tempt-
ing, the requisite “clean environment” needed to maintain
a high incidence of diabetes in a NOD colony is at odds
with the infectious disease concept. Alternatively, normal
cellular turnover during tissue remodeling has become a
favored hypothesis (7). In this scenario, tissue-associated
antigens would be released from -cells as an unintended
consequence of organ development, leading to the priming
and activation of islet-reactive T-cells in susceptible
individuals.
Several islet antigens are able to solicit immune re-
sponses in naive NOD mice, including GAD65, one of a few
-cell proteins known to induce autoantibody; Th cells;
and cytotoxic T-lymphocytes in pre-diabetic mice (8,9)
and in recent-onset type 1 diabetic humans (10,11). Treat-
ments that tolerize, deviate, or alter the anti-GAD65 re-
sponse in NOD mice typically delay or prevent insulitis
and diabetes (8,9). Interestingly, the immune deviation
associated with GAD65-induced protection often spreads
to other islet speciﬁcities as well (12), further supporting
the view of a temporal pattern of immune responses in the
initial stages of type 1 diabetes. Part of the charm of the
molecular mimicry model is the provision of a single
epitope as the initiator, which could likely manifest as a
sequential pattern of autoimmunity as described in the
evolution of autoimmunity in young NOD mice (8,9).
However, if tissue remodeling is indeed the inciting event
for -cell autoimmunity, then we are left to explain why
GAD65-speciﬁc responses preferentially expand to detect-
able levels early (Fig. 1) and why they can become
inﬂuential to other antigenic speciﬁcities.
Previously, Jaeckel et al. (13) created NOD.GAD65.tg
mice to test the premise that GAD65-speciﬁc immunity is
requisite for the progression of type 1 diabetes. By placing
a modiﬁed form of GAD65 under the control of the
invariant chain promoter, the researchers were indeed
able to suppress the response to GAD65 without altering
the course of type 1 diabetes, which not only challenged
the notion of GAD65 as a necessary autoantigen but to
some it cast doubts on the antigen’s ability to contribute to
any phase of the disease. To conﬁrm the putative toler-
ance, they analyzed T-cell responses following immuniza-
tion with rGAD65. In this issue of Diabetes (14), two labs
have collaborated and enhanced the examination of the
spontaneous T-cell responses to -cell antigens in
NOD.GAD65.tg mice. Tian et al. (14) found the responses
to GAD65 were signiﬁcantly altered in all age-groups of the
transgenic mice but were detectable nonetheless. Intrigu-
ingly—but consistent with previous reports from Tian et
al. (12)—the blunted responses to GAD65 appear to have
an age-dependent impact on other -cell speciﬁcities. In
addition, their results suggest that absolute central toler-
ance to GAD65 is elusive in NOD mice, even when
extraordinary efforts are taken to express the antigen
throughout development and in the manner expected to
induce deletion of the cognate-speciﬁc T-cells. This would
seem to highlight the importance of peripheral tolerance,
as noted by the authors, and perhaps explain why treat-
ment with GAD65/GAD65 peptides has been fairly effective
in reducing the incidence of type 1 diabetes in NOD mice,
in contrast to transgenic expression models that have
produced conﬂicting results (13,15,16).
Clearly, a robust T-cell response to GAD65 is not
required for type 1 diabetes in NOD mice (13,17). Yet, does
this disqualify the antigen as a contributor to type 1
diabetes or as a viable target in immunotherapy? What
remains is a need to advance our understanding of the
mechanisms that create a connection between GAD65
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important, the regulation (12) of other autoreactive T-
cells. The earliest events in islet inﬂammation lead to the
propagation of diabetogenic T-cells; thus, prevention ne-
cessitates knowledge of the steps that occur prior to the
recruitment of these effectors.
The notions of tissue remodeling and sequential expan-
sion of antigen-speciﬁc T-cell repertoires may seem incom-
patible. However, if we cease to assume that all antigens
are “created equal” and take into consideration the pow-
erful inﬂuence of antigenic vigor, we can reconcile that the
simultaneous release of antigen is not synonymous to
simultaneous priming. Perhaps GAD65 is one of the more
immunogenic islet antigens because GAD65 peptides and
plasmids readily recruit adaptive immune responses. Hu-
man GAD65 is less soluble than its isomeric counterpart
GAD67 and predominantly bound to vesicular membranes
(sequestered) in the cell (18,19), features that could en-
hance GAD65’s capture by antigen-presenting cells.
GAD65’s inﬂuence in type 1 diabetes may relate more to its
ability to overcome tolerance, activate cognate-speciﬁc
T-cells, and dictate the milieu of the islets rather than to its
direct diabetogenic potential (Fig. 1).
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FIG. 1. Following the release of -cell antigens, the frequency of
GAD65-reactive T-cells expands in the pancreatic nodes of young NOD
mice, reaching detectable levels ahead of clonotypes speciﬁc for other
islet antigens. Inadequate tolerance, due in part to limited expression
in the periphery and/or enhanced antigen presentation, may help drive
the preferential expansion of clones that recognize dominant GAD65
epitopes.
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